Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
East Asian patients achieve 30 to 50% higher atorvastatin plasma levels than European-ancestry patients at identical doses. Here is what the pharmacogenomic data, clinical trials, and FDA labeling say about adjusting Lipitor therapy for this population.
Read clinical reviewAn evidence-based review of atorvastatin efficacy differences in Black and African ancestry patients, covering pharmacogenomics, ethnicity-stratified trial data, and clinical dosing considerations.
Read clinical reviewEast Asian patients metabolize atorvastatin differently due to SLCO1B1, CYP2C19, and ABCG2 variants. Learn how pharmacogenomics, ethnicity-stratified trial data, and current guidelines inform safer, more effective Lipitor dosing for East Asian patients.
Read clinical reviewEast Asian patients taking atorvastatin (Lipitor) face distinct pharmacogenomic risks, different optimal starting doses, and ethnicity-specific myopathy thresholds. Here is what the clinical data says.
Read clinical reviewAtorvastatin dosing in Hispanic and Latino patients: ethnicity-stratified trial data, CYP3A4/SLCO1B1 pharmacogenomics, diabetes risk, and ACC/AHA guideline-concordant recommendations from the HealthRX.com medical team.
Read clinical review